Department of Medicine, University of California, San Francisco, Medical Center, USA.
Am J Surg. 2010 Nov;200(5):659-64. doi: 10.1016/j.amjsurg.2010.07.021.
For patients with compensated cirrhosis, transcatheter arterial embolization with and without additive chemotherapy has been shown to improve survival. The aim of this study was to compare periprocedural complications in a population with hepatitis C virus-related hepatocellular carcinoma to evaluate for differences in complications by severity of liver disease.
Patients with unresectable hepatocellular carcinoma treated by transcatheter arterial embolization with or without additive chemotherapy procedures from 2003 to 2006 were retrospectively reviewed and compared by Child-Pugh (CP) class. A total of 141 embolizations were done in 76 patients.
Complication rates were seen in 27% of CP class A and 17% of CP class B patients. There was no significant difference in the grade of complications between the 2 groups or between procedure types. Survival rate was dependent on the degree of liver dysfunction (3-year CP class A, 49%; CP class B, 13%; P = .0048).
Embolization procedures to treat hepatitis C virus-related hepatocellular carcinoma can be performed safely with low morbidity and mortality rates, even in patients with a compromised hepatic reserve.
对于代偿期肝硬化患者,经导管动脉栓塞术联合或不联合附加化疗已被证明可提高生存率。本研究的目的是比较丙型肝炎病毒相关肝细胞癌患者人群的围手术期并发症,以评估肝疾病严重程度对并发症的差异。
回顾性分析了 2003 年至 2006 年期间接受经导管动脉栓塞术联合或不联合附加化疗治疗的不可切除肝细胞癌患者,并按 Child-Pugh(CP)分级进行比较。共对 76 例患者进行了 141 次栓塞。
CP 分级 A 组和 CP 分级 B 组的并发症发生率分别为 27%和 17%。两组之间或两种手术类型之间的并发症严重程度无显著差异。生存率取决于肝功能障碍的程度(3 年 CP 分级 A 组为 49%;CP 分级 B 组为 13%;P=0.0048)。
即使在肝功能储备受损的患者中,经导管动脉栓塞术治疗丙型肝炎病毒相关肝细胞癌也可安全进行,发病率和死亡率均较低。